Drug Profile

Orziloben - NorthSea Therapeutics

Alternative Names: NST-6179; SEFA-6179

Latest Information Update: 28 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pronova BioPharma
Developer NorthSea Therapeutics
Class Antifibrotics; Hepatoprotectants; Omega 3 fatty acids; Unsaturated fatty acids
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Liver disorders

Most Recent Events

28 Jan 2025 No recent reports of development identified for phase-I development in Liver-disorders(In volunteers) in United Kingdom (PO)
24 Dec 2024 Chemical structure information added.
23 Aug 2024 NorthSea Therapeutics completes a phase I trial in healthy volunteers in the United Kingdom (PO) (ISRCTN12367117)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com